World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
130
Citations
88599
World Ranking
2439
National Ranking
1382

Brian I. Rini publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Brian I. Rini sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 1,002 publications — 94th percentile

94% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Brian I. Rini D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Brian I. Rini sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 130 D-Index — 88th percentile

88% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Brian I. Rini is affiliated with Vanderbilt University Medical Center in the United States. Their research primarily addresses the treatment and biology of renal cell carcinoma and related cancers, contributing to both clinical and molecular understanding within the oncology field.

Their publication record includes numerous works in leading medical and oncology journals. Frequent publication venues include:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • European Urology
  • The Oncologist
  • ESMO Open

Their main fields of study encompass Medicine and Biochemistry, Genetics and Molecular Biology. Within these areas, their subfields cover Pulmonary and Respiratory Medicine, Oncology, Molecular Biology, Cancer Research, and Economics and Econometrics.

Brian I. Rini's research topics focus strongly on:

  • Renal cell carcinoma treatment
  • Cancer Immunotherapy and Biomarkers
  • Renal and related cancers
  • Cancer Genomics and Diagnostics
  • Economic and Financial Impacts of Cancer
  • Pancreatic and Hepatic Oncology Research
  • Bladder and Urothelial Cancer Treatments

Recent papers reflect areas at the intersection of clinical oncology and immunotherapy. Notable publications include:

  • Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study, 2020, The Lancet
  • Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial, 2020, The Lancet Oncology
  • Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial, 2020, ESMO Open
  • Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade, 2020, Cancer Cell
  • The immunology of renal cell carcinoma, 2020, Nature Reviews Nephrology

Collaborations have been an integral part of their work, frequently co-authoring with researchers such as Toni K. Choueiri, Laurence Albigès, Robert J. Motzer, David F. McDermott, and Michael B. Atkins. These co-authors are prominent within oncology and related biomedical research, underlining a network focused on cancer treatment and translational studies.

Best Publications

  • Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

    Robert J Motzer;Nizar M Tannir;David F McDermott;Osvaldo Arén Frontera

  • Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

    Brian I. Rini;Elizabeth R. Plimack;Viktor Stus;Rustem Gafanov

  • Renal cell carcinoma

    Brian I Rini;Steven C Campbell;Bernard Escudier

  • Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma

    Robert J. Motzer;M. Dror Michaelson;Bruce G. Redman;Gary R. Hudes

  • Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

    Robert J. Motzer;Konstantin Penkov;John Haanen;Brian Rini

  • Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial

    Brian I. Rini;Bernard Escudier;Piotr Tomczak;Andrey Kaprin

  • Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study

    Daniel Y.C. Heng;Wanling Xie;Meredith M. Regan;Mark A. Warren

  • Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.

    Nicole M. Kuderer;Toni K. Choueiri;Dimpy P. Shah;Yu Shyr

  • Sunitinib in Patients With Metastatic Renal Cell Carcinoma

    Robert J. Motzer;Brian I. Rini;Brian I. Rini;Ronald M. Bukowski;Brendan D. Curti

  • Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma

    Toni K. Choueiri;Bernard Escudier;Thomas Powles;Paul N. Mainwaring

  • Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial

    Robert J. Motzer;Brian I. Rini;David F. McDermott;Bruce G. Redman

  • Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial

    Brian I Rini;Thomas Powles;Michael B Atkins;Bernard Escudier

  • Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206

    Brian I Rini;Susan Halabi;Jonathan E. Rosenberg;Walter M. Stadler

  • Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma

    David F. McDermott;Mahrukh A. Huseni;Michael B. Atkins;Robert J. Motzer

  • External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study

    Daniel Y.C. Heng;Wanling Xie;Meredith M. Regan;Lauren C. Harshman

  • Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients

    Jennifer S. Ko;Arnold H. Zea;Brian I. Rini;Joanna L. Ireland

  • Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial

    Toni K Choueiri;Bernard Escudier;Thomas Powles;Nizar M Tannir

  • Phase III Trial of Bevacizumab Plus Interferon Alfa Versus Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: Final Results of CALGB 90206

    Brian I. Rini;Susan Halabi;Jonathan E. Rosenberg;Walter M. Stadler

  • Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial

    Robert J Motzer;Bernard Escudier;Piotr Tomczak;Thomas E Hutson

  • Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial

    Robert J. Motzer;Brian I. Rini;David F. McDermott;Osvaldo Arén Frontera

Frequent Co-Authors

Toni K. Choueiri
Toni K. Choueiri Harvard University
Robert J. Motzer
Robert J. Motzer Memorial Sloan Kettering Cancer Center
David F. McDermott
David F. McDermott Beth Israel Deaconess Medical Center
Bernard Escudier
Bernard Escudier Institut Gustave Roussy
Thomas Powles
Thomas Powles Queen Mary University of London
Michael B. Atkins
Michael B. Atkins Georgetown University
James H. Finke
James H. Finke Cleveland Clinic Lerner College of Medicine
Ronald M. Bukowski
Ronald M. Bukowski Cleveland Clinic
Elizabeth R. Plimack
Elizabeth R. Plimack Fox Chase Cancer Center
Steven C. Campbell
Steven C. Campbell Cleveland Clinic

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students considering Medicine in the USA, there are multiple online degree options and career pathways to explore. Those already working as registered nurses might look into rn to bsn programs without clinicals. These programs are designed for flexibility, letting nurses advance their education without traditional in-person requirements.

For those interested in advancing further, doctoral nursing pathways offer accelerated options. The shortest dnp programs provide a streamlined route for qualified nurses to earn their Doctor of Nursing Practice in less time. Some students may also prefer easiest dnp programs, which focus on user-friendly curricula and manageable workloads.

If you’re just beginning your journey, consider starting with a fast lpn program. These online courses help students become Licensed Practical Nurses quickly, offering a stepping stone to further medical education and employment.

Exploring these varied online programs can help you find a pathway that suits your goals, schedule, and learning preferences as you pursue a career in medicine.

Best Scientists Citing Brian I. Rini

Trending Scientists

Recently Published Articles